Nexentis Technologies Inc. has taken an important step by filing a preliminary proxy statement for its upcoming annual stockholder meeting. This filing, dated November 9, 2026, is crucial as it outlines significant proposals that will require shareholder approval.

The annual meeting is scheduled for December 30, 2026, at 4:30 p.m. Israel time (9:30 a.m. EST). It will be held at the offices of the Company’s legal counsel in Israel. The meeting will cover several key items, including the re-election of directors, the issuance of securities, and the appointment of auditors.

Background

Nexentis Technologies Inc. is categorized under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company is listed on the Nasdaq under the ticker NXTS. As an emerging growth company, Nexentis is navigating the complexities of the pharmaceutical industry, which is characterized by rapid innovation and regulatory scrutiny.

What the Filing Says

The preliminary proxy statement outlines several proposals for the upcoming stockholder meeting:

  • Re-election of three Class II directors for a three-year term, namely Amitay Weiss, Liat Sidi, and Asaf Itzhaik.
  • Approval of securities issuance in non-public offerings at a maximum discount of 20% below market price, in accordance with Nasdaq Listing Rule 5635(d).
  • Ratification of Brightman Almagor Zohar & Co. as the independent auditors for the fiscal year ending December 31, 2026.
  • Approval for the issuance of shares related to a proposed convertible note financing facility, including up to $10 million in unsecured convertible promissory notes.
  • Amendment to increase shares available under the Save Foods, Inc. 2022 Share Incentive Plan.

The board of directors has recommended a vote in favor of all proposals.

Impact

This filing may significantly affect Nexentis' shareholders, as their votes will determine the direction of the company regarding its governance and financial strategies. The decisions made at this meeting will also resonate within the pharmaceutical preparations industry, as they reflect broader trends in shareholder engagement and corporate governance.

What's Next

Following this filing, stockholders are encouraged to participate in the upcoming meeting and cast their votes on the outlined proposals. The board has emphasized the importance of shareholder participation in the company’s affairs.

For more details, stockholders are referred to the accompanying proxy statement for further information regarding the matters to be considered at the meeting.